Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Quick Order
EGFR
epidermal growth factor receptor
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.
Perinatal increases in TGF-{alpha} disrupt the saccular phase of lung morphogenesis and cause remodeling: microarray analysis. Kramer EL, Deutsch GH, Sartor MA, Hardie WD, Ikegami M, Korfhagen TR, Le Cras TD. American journal of physiology. Lung cellular and molecular physiology. 2007 293:L314-27. (WB)
[PubMed:17468132]
2
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Kumar N, Afeyan R, Kim HD, Lauffenburger DA. Molecular pharmacology. 2008 73:1668-78. (ICC)
[PubMed:18349105]
3
Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway. Kim CE, Lee SJ, Seo KW, Park HM, Yun JW, Bae JU, Bae SS, Kim CD. Toxicology and applied pharmacology. 2010 245:76-82. (WB)
[PubMed:20153347]
4
Nuclear translocation of type I transforming growth factor receptor confers a novel function in RNA processing. Chandra M, Zang S, Li H, Zimmerman LJ, Champer J, Tsuyada A, Chow A, Zhou W, Yu Y, Gao H, Ren X, Lin RJ, Wang SE. Molecular and cellular biology. 2012 32:2183-95.
[PubMed:22473997]
[PMC:PMC3372271]
5
Liquid crystal droplet-based amplification of microvesicles that are shed by mammalian cells. Tan LN, Wiepz GJ, Miller DS, Shusta EV, Abbott NL. The Analyst. 2014 139:2386-96. (WB; Human)[Full Text Article]
[PubMed:24667742]
[PMC:PMC4212983]
6
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunja LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KW, Keller E, Thomas D, Nagrath S, Morgan T, Day ML. Cancer research. 2017 77:74-85. (IP; Human)[Full Text Article]
[PubMed:27793843]
[PMC:PMC5214538]
7
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM. Molecular cancer therapeutics. 2015 14:1141-51. (WB; Human)[Full Text Article]
[PubMed:25731184]
Related Antibodies: LS-C6625.
Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. Christina Demuth, Morten Nørgaard Andersen, Kristine Raaby Jakobsen, Anne Tranberg Madsen, Boe Sandahl Sørensen. Oncotarget. 2017 September;8:68221-68229. [Full Text Article]
[PubMed:28978110]
[PMC:PMC5620250]
Related Antibodies: LS-C6611.
10
Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, Taylor L, Tate SA, Hardy WR, Colwill K, Dai AY, Bagshaw R, Dennis JW, Gingras AC, Daly RJ, Pawson T. Nature. 2013 Jul;499:166-71. [Full Text Article]
[PubMed:23846654]
Related Antibodies: LS-C6640.
11
Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. Aggerholm-Pedersen N, Demuth C, Safwat A, Meldgaard P, Kassem M, Sandahl Sorensen B. Stem cells international. 2016 2016:9601493. (WB; Human)[Full Text Article]
[PubMed:26788073]
[PMC:PMC4693025]
Related Antibodies: LS-C6611.
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.
PLEASE NOTE
For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.
The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).